JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox — United States, May 22, 2022–January 31, 2023
Lauren Owens, Dustin W. Currie, Ellen A. Kramarow, Safana Siddique, Megan Swanson, Rosalind J. Carter, Jennifer L. Kriss, Peter Boersma, Florence C. Lee, Ian H. Spicknall, Elizabeth Hurley, María Zlotorzynska, Adi V. Gundlapalli
Abstract
were administered. Through the week of August 20, 2022, the predominant route of administration was subcutaneous, after which intradermal administration became predominant, in accordance with FDA guidance. As of January 31, 2023, 1-dose and 2-dose (full vaccination) coverage among persons at risk for mpox is estimated to have reached 36.7% and 22.7%, respectively. Despite a steady decline in mpox cases from a 7-day daily average of more than 400 cases on August 1, 2022, to five cases on January 31, 2023, vaccination for persons at risk for mpox continues to be recommended (1). Targeted outreach and continued access to and availability of mpox vaccines to persons at risk are important to help prevent and minimize the impact of a resurgence of mpox.